Ziprasidone Hydrochloride

Treats schizophrenia. Sold as Geodon. Every FDA application for this active ingredient: 2 branded and 9 generic.

As of Nov 15, 2026, FDA lists 11 applications for Ziprasidone Hydrochloride (sold as Geodon), first approved Feb 5, 2001, with 3 new uses approved and 0 published complete response letters.

First approved: Feb 5, 2001
Applications: 11
New uses approved: 3
Complete response letters: 0
Medicare spending, 2025: $44.3M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name


Ziprasidone HCl	Part D	$39.6M	-3%	73,550
Geodon	Part D	$4.7M	-13%	307

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

ZIPRASIDONE 20 MG/ML VIAL: $21.81 per unitGeneric · +17% in a year
ZIPRASIDONE HCL 20 MG CAPSULE: $0.218 per unitGeneric · -29% in a year
ZIPRASIDONE HCL 40 MG CAPSULE: $0.265 per unitGeneric · +3% in a year
ZIPRASIDONE HCL 60 MG CAPSULE: $0.332 per unitGeneric · +3% in a year
ZIPRASIDONE HCL 80 MG CAPSULE: $0.272 per unitGeneric · -23% in a year
GEODON 80 MG CAPSULE: $31.11 per unitBrand · +5% in a year

Clinical Trials

3 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.Apathy, Schizophrenia · Louisiana State University Health Sciences Center Shreveport	Phase 3	Recruiting	Jul 1, 2024
Maternal And Infant Antipsychotic StudyAntipsychotics, Pregnancy · Icahn School of Medicine at Mount Sinai	—	Recruiting	Sep 22, 2023
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For SchizophreniaSchizophrenia · University of Arizona	Phase 1	Active, not recruiting	Dec 19, 2018

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Feb 5, 2001	GeodonNDA 20825 · New molecular entity	Viatris	34	Marketed
Mar 29, 2006	GeodonNDA 21483 · New dosage form	Pfizer Inc	9	Discontinued
Mar 2, 2012	Ziprasidone HydrochlorideANDA 77560	Lupin Pharms	10	Discontinued
Mar 2, 2012	Ziprasidone HydrochlorideANDA 77561	Apotex	12	Marketed
Mar 2, 2012	Ziprasidone HydrochlorideANDA 77565	Dr Reddys Labs Inc	12	Marketed
Jun 1, 2012	Ziprasidone HydrochlorideANDA 77562	Sandoz Inc	7	Marketed
Sep 5, 2012	Ziprasidone HydrochlorideANDA 90348	Chartwell Rx	3	Marketed
Oct 10, 2013	Ziprasidone HydrochlorideANDA 202395	Mylan	2	Discontinued
Dec 27, 2016	Ziprasidone HydrochlorideANDA 204117	Aurobindo Pharma	5	Marketed
Feb 17, 2017	Ziprasidone HydrochlorideANDA 204375	Macleods Pharms	4	Marketed
Aug 22, 2017	Ziprasidone HydrochlorideANDA 208988	Zydus Lifesciences	2	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA